Blog: Blog2

GPCR News

A cryptic mode of GPCR regulation revealed

October 2022 "Over three decades of research have provided thorough insights into G protein-coupled receptor (GPCR) regulation. In a...

Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future

October 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealised,...

Ginsenoside Rg5 allosterically interacts with P2RY12 and ameliorates deep venous thrombosis by...

September 2022 Ginsenoside Rg5 allosterically interacts with P2RY12 and ameliorates deep venous thrombosis by counteracting neutrophil...

Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug...

Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..

September 2022 Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced...

Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84

August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of effective medicines many GPCRs...

Developing the Cannabinoid Receptor 2 (CB2) pharmacopeia: past, present, and future

August 2022 "Cannabinoid Receptor 2 (CB2) is a G protein-coupled receptor (GPCR) with considerable, though as yet unrealized, therapeutic...